ArrudaV.R, FieldsP.A, MilnerRet al.2001. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol. Ther., 4:586–592.
3.
BrandonE.F., HermsenH.P., van EijkerenJ.C., TiesjemaB. 2010. Effect of administration route on the biodistribution and shedding of replication-deficient AAV2: a qualitative modelling approach. Curr. Gene Ther., 10:91–106.
4.
BRMAC (Biological Response Modifiers Advisory Committee). 2000. Minutes of meeting, Food and Drug Administration Center for Biologics Evaluation and Research. November16, 2000.
5.
BRMAC (Biological Response Modifiers Advisory Committee). 2002. Minutes of meeting, Food and Drug Administration Center for Biologics Evaluation and Research. May10, 2002.
6.
European Medicines Agency (EMA). 2008. Guideline on scientific requirements for the environmental risk assessment of gene therapy medicinal products. 1–14.
7.
Food and Drug Administration (FDA). 1998. Guidance for human somatic cell therapy and gene therapy. 26.
8.
Food and Drug Administration (FDA). 2006. Gene therapy clinical trials—observing subjects for delayed adverse events. 10–11.
9.
Food and Drug Administration (FDA). 2012. Draft guidance on preclinical assessment of investigational cellular and gene therapy products. 26.
10.
GoninP, GaillardC. 2004. Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther.Suppl. 1:S98–S108.
11.
KayM.A, MannoC.S, RagniM.Vet al.2000. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet., 24:257–261.
12.
MannoC.S, PierceG.F, ArrudaV.Ret al.2006. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med., 12:342–347.
13.
MiskinJ, MitrophanousK.Oxford BioMedica, personal communication, December2012.
14.
Office of Biotechnology Activities–Recombinant DNA Advisory Committee (OBA-RAC). 1999. Minutes of meeting, National Institutes of Health. March11–12, 1999.
15.
Office of Biotechnology Activities–Recombinant DNA Advisory Committee (OBA-RAC). 2001. Minutes of meeting, National Institutes of Health, December6, 2001.
16.
Office of Biotechnology Activities–Recombinant DNA Advisory Committee (OBA-RAC). 2002. Minutes of meeting, National Institutes of Health. March7–8, 2002.
17.
RoehlH.H, LeibbrandtM.E, GreengardJ.Set al.2000. Analysis of testes and semen from rabbits treated by intravenous injection with a retroviral vector encoding the human factor VIII gene: no evidence of germ line transduction. Hum. Gene Ther., 11:2529–2540.
18.
SheetsR.L, SteinJ, BailerR.Tet al.2008. Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts. J. Immunotoxicol., 5:315–335.
19.
TiesjemaB, HermsenH.P, van EijkerenJ.C, BrandonE.F. 2010. Effect of administration route on the biodistribution and shedding of replication-deficient HAdV-5: a qualitative modelling approach. Curr. Gene Ther., 10:107–27.
20.
VatsanR.2010. CBER perspective on comparability, 30th annual ACT meeting. International Journal of Toxicology, 29:112.
